Surveillance in von Hippel‐Lindau disease (vHL)
- 21 December 2009
- journal article
- Published by Wiley in Clinical Genetics
- Vol. 77 (1) , 49-59
Abstract
Poulsen MLM, Budtz‐Jørgensen E, Bisgaard ML. Surveillance in von Hippel‐Lindau disease (vHL).von Hippel‐Lindau disease (vHL) is a hereditary multisystem cancer syndrome requiring lifelong prophylactic surveillance. Current surveillance recommendations rely on best medical judgement and no evidence of effect exists. We aimed to evaluate the capability of surveillance in manifestation detection, before these turn symptomatic, in order to prevent disabling or even fatal outcomes. We focus on surveillance of central nervous system (CNS) hemangioblastomas, retinal hemangiomas and renal cell carcinoma (RCC) as these have the most severe consequences. On the basis of full medical records from 54 living vHL‐mutation carriers, risks of intercurrent manifestations in‐between surveillance examinations were determined and clinical consequences of surveillance findings evaluated. Current recommendations of annual ophthalmic and abdominal examinations corresponded to acceptably low intercurrent manifestation risks (1.7% and 1.2%, respectively), whereas recommendations of biennial CNS imaging corresponded to a risk of 7.2%. Annual CNS examinations, however, significantly reduces this risk to 2.7%. Furthermore, most CNS manifestations found due to surveillance (71%, 106 of 150) had clinical consequence for the patient. Also, pre‐symptomatic surveillance increased cumulative incidence of clinical vHL diagnosis from 46% to 72% and from 89% to 94% by age 30 and 50 years, respectively. The present results promote optimization of surveillance, expectantly improving clinical vHL outcomes.Keywords
This publication has 36 references indexed in Scilit:
- Frequency of Von Hippel‐Lindau germline mutations in classic and non‐classic Von Hippel‐Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation‐dependent probe amplificationClinical Genetics, 2007
- Benefits of Screening in von Hippel-Lindau Disease – Comparison of Morbidity Associated with Initial Tumours in Affected Parents and ChildrenHormone Research in Paediatrics, 2006
- Von Hippel–Lindau disease germline mutations in Mexican patients with cerebellar hemangioblastomaJournal of Neurosurgery, 2006
- Clinical management of Von Hippel–Lindau (VHL) diseaseThe Netherlands Journal of Medicine, 2001
- VHL c.505 T>C mutation confers a high age related penetrance but no increased overall mortalityJournal of Medical Genetics, 2001
- An Analysis of Phenotypic Variation in the Familial Cancer Syndrome von Hippel–Lindau Disease: Evidence for Modifier EffectsThe American Journal of Human Genetics, 1998
- A genetic register for von Hippel-Lindau disease.Journal of Medical Genetics, 1996
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993
- Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma.Journal of Medical Genetics, 1990
- Von Hippel-Lindau Disease Affecting 43 Members of a Single KindredMedicine, 1989